Aug. 19 at 7:45 PM
$ADMA
A)We are likely to see in-between
$10M to
$40M higher adjusted earnings this year compared with last year.
B)ASCENIV is a strong potential blockbuster candidate. And SG-001, another plasma-derived product with potentially significant commercial potential, could join ASCENIV and contribute to ADMA's growth in the coming years.
That's a goldmine - or a "plasmamine." :)
C)The strong share-repurchase program remains intact as well, further supporting per-share value.
D)At these fundamentals, I see no fundamental reason why ADMA shouldn't be able to return to at least
$20+ per share in the near term and continue growing from there, assuming the company executes on its guidance and ASCENIV continues its strong growth
